Thiel Bio Fund

Thiel Bio operates as a venture capital firm, focusing its investments on early to growth-stage companies across the life sciences sector. It strategically allocates capital to enterprises developing therapeutics, medical devices, robotics, and advanced biotechnology applications. The firm’s objective is to support innovations poised to significantly impact human health and biological industries.

Jason Camm, previously chief medical officer at Thiel Capital, founded the firm. An osteopath by background, Camm established Thiel Bio, recognizing a clear opportunity for specialized capital to accelerate promising biomedical ventures. His expertise bridges scientific understanding with investment strategy, guiding the firm’s focus on high-potential life science opportunities.

Thiel Bio primarily invests in innovative life science companies, offering them financial backing and strategic partnership. The firm’s mission is to catalyze development of groundbreaking solutions for critical global health challenges. Its vision involves cultivating a robust portfolio of ventures that deliver transformative and lasting biotechnological advancements.